Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRA Biofrontera	$2.60	$2.95	$2.09 ▼ $7.54	$73.73M	1.02	27,512 shs	7,263 shs
KALV KalVista Pharmaceuticals	$14.91 -1.0%	$12.43	$7.30 ▼ $15.98	$741.33M	-0.04	546,917 shs	2.98 million shs
MCRB Seres Therapeutics	$11.52 +6.2%	$8.30	$6.53 ▼ $30.60	$100.57M	2.75	134,066 shs	61,613 shs
MNOV MediciNova	$1.27 +1.6%	$1.38	$1.12 ▼ $2.55	$62.29M	0.4	36,297 shs	21,136 shs
OCUL Ocular Therapeutix	$9.94 +3.4%	$8.22	$5.79 ▼ $11.78	$1.58B	1.43	1.42 million shs	1.33 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRA Biofrontera	0.00%	0.00%	0.00%	0.00%	0.00%
KALV KalVista Pharmaceuticals	+26.55%	+33.16%	+4.87%	+45.93%	+27.74%
MCRB Seres Therapeutics	-4.45%	-2.34%	+31.83%	+4.31%	-33.19%
MNOV MediciNova	-0.79%	-4.58%	-11.35%	+0.81%	-11.35%
OCUL Ocular Therapeutix	+2.67%	+3.56%	+6.54%	+59.63%	+44.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	4.2328 of 5 stars	3.6	1.0	0.0	4.4	3.1	2.5	0.6
MCRB Seres Therapeutics	3.5406 of 5 stars	2.9	2.0	0.0	4.6	2.8	0.8	0.0
MNOV MediciNova	1.8487 of 5 stars	3.8	2.0	0.0	0.0	0.0	0.8	0.0
OCUL Ocular Therapeutix	3.9253 of 5 stars	3.5	1.0	0.0	4.1	2.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRA Biofrontera	0.00	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	72.48% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	546.20% Upside
MNOV MediciNova	3.50	Strong Buy	$7.00	451.18% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.33	74.56% Upside

Current Analyst Ratings Breakdown

Latest OCUL, MNOV, MCRB, BFRA, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/16/2025	MNOV MediciNova	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$6.00 ➝ $5.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/9/2025	MNOV MediciNova	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRA Biofrontera	$36.19M	2.04	N/A	N/A	$0.35 per share	7.43
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
MCRB Seres Therapeutics	$126.32M	0.79	N/A	N/A	$1.61 per share	7.08
MNOV MediciNova	N/A	N/A	N/A	N/A	$1.07 per share	N/A
OCUL Ocular Therapeutix	$63.72M	24.83	N/A	N/A	$2.01 per share	4.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRA Biofrontera	-$14.88M	-$0.73	N/A	∞	N/A	-59.44%	-93.31%	-24.02%	N/A
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
MNOV MediciNova	-$11.04M	-$0.23	N/A	N/A	N/A	N/A	-20.77%	-19.68%	8/6/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)

Latest OCUL, MNOV, MCRB, BFRA, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	MNOV MediciNova	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRA Biofrontera	0.13	1.26	1.13
KALV KalVista Pharmaceuticals	N/A	10.44	10.44
MCRB Seres Therapeutics	N/A	2.11	2.11
MNOV MediciNova	N/A	17.66	17.66
OCUL Ocular Therapeutix	0.26	10.22	10.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRA Biofrontera	60.07%
KALV KalVista Pharmaceuticals	N/A
MCRB Seres Therapeutics	59.34%
MNOV MediciNova	9.90%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
BFRA Biofrontera	N/A
KALV KalVista Pharmaceuticals	10.50%
MCRB Seres Therapeutics	4.70%
MNOV MediciNova	13.60%
OCUL Ocular Therapeutix	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRA Biofrontera	138	28.36 million	N/A	Not Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
MNOV MediciNova	10	49.05 million	42.38 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable

OCUL, MNOV, MCRB, BFRA, and KALV Headlines

Recent News About These Companies

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 5.5% - Here's What Happened

4 hours ago | marketbeat.com

847,468 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Peregrine Capital Management LLC

July 1, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 7.7% - What's Next?

June 30, 2025 | marketbeat.com

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - Nasdaq

June 27, 2025 | nasdaq.com

Ocular Therapeutix sharpens focus with retina-centric rebrand

June 27, 2025 | fiercepharma.comF

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

June 26, 2025 | finance.yahoo.com

Ocular Therapeutixâ„¢ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

June 26, 2025 | globenewswire.com

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

June 25, 2025 | zacks.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up - Here's Why

June 24, 2025 | marketbeat.com

Deltec Asset Management LLC Has $19.91 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 21, 2025 | marketbeat.com

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

June 18, 2025 | ophthalmologytimes.comO

Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years

June 17, 2025 | uk.finance.yahoo.com

Assenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 17, 2025 | marketbeat.com

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

June 16, 2025 | globenewswire.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Brokerages

June 15, 2025 | marketbeat.com

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

June 11, 2025 | ophthalmologytimes.comO

Courier Capital LLC Boosts Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 10, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 8, 2025 | marketbeat.com

Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD

June 2, 2025 | ophthalmologytimes.comO

H.C. Wainwright maintains $15 target on Ocular Therapeutix stock

May 31, 2025 | investing.com

Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews

May 29, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, MNOV, MCRB, BFRA, and KALV Company Descriptions

Biofrontera NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

KalVista Pharmaceuticals NASDAQ:KALV

$14.91 -0.15 (-1.00%)

As of 03:51 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Seres Therapeutics NASDAQ:MCRB

$11.52 +0.67 (+6.18%)

As of 03:51 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MediciNova NASDAQ:MNOV

$1.27 +0.02 (+1.60%)

As of 03:50 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Ocular Therapeutix NASDAQ:OCUL

$9.94 +0.33 (+3.43%)

As of 03:51 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time